Satellos receives clearance by FDA to initiate Phase 2 study in Duchenne

Satellos Biosciences has received Investigational New Drug (IND) clearance from the FDA, as well as other global regulatory agencies, to conduct a 3-month placebo-controlled Phase 2 study of SAT-3247 in ambulatory individuals with Duchenne.  SAT-3247 is an oral, small molecule drug aiming to regenerate skeletal muscle that is lost in Duchenne.  Satellos expects the first participant to be enrolled by the end of the year, and will report interim data in Q2 2026.  

Read the press release HERE